0001104659-21-024408.txt : 20210216
0001104659-21-024408.hdr.sgml : 20210216
20210216172705
ACCESSION NUMBER: 0001104659-21-024408
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210211
FILED AS OF DATE: 20210216
DATE AS OF CHANGE: 20210216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Smith Hunter C
CENTRAL INDEX KEY: 0001636385
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38223
FILM NUMBER: 21641062
MAIL ADDRESS:
STREET 1: C/O GENESEE & WYOMING INC.
STREET 2: 20 WEST AVENUE
CITY: DARIEN
STATE: CT
ZIP: 06820
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RHYTHM PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001649904
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 462159271
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 222 BERKELEY STREET
STREET 2: 12TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 857-264-4280
MAIL ADDRESS:
STREET 1: 222 BERKELEY STREET
STREET 2: 12TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: RHYTHM METABOLIC, INC.
DATE OF NAME CHANGE: 20150803
4
1
tm216849-2_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-02-11
0
0001649904
RHYTHM PHARMACEUTICALS, INC.
RYTM
0001636385
Smith Hunter C
222 BERKELEY STREET, 12TH FLOOR
BOSTON
MA
02116
0
1
0
0
Chief Financial Officer
Restricted Stock Units
2021-02-11
4
A
0
9375
0
A
Common Stock
9375
9375
D
Stock Option (Right to Buy)
30.66
2021-02-11
4
A
0
56250
0
A
2031-02-10
Common Stock
56250
56250
D
Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date
The stock options were granted on February 11, 2021. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
/s/ Hunter C. Smith
2021-02-16